“We are excited to present these data, demonstrating the striking effects that NYX-458 has on cognitive impairment in a highly translatable non-human primate model of Parkinson’s disease,” said
Oral Presentation Details:
Presentation Title: The NMDAr modulator NYX-458 results in long-lasting improvement in several cognitive domains in a primate model of Parkinson’s disease cognitive impairment
Time and Location:
Poster Presentation Details:
Presentation Title: The NMDAr modulator NYX-458 results in long-lasting improvement in several cognitive domains in a primate model of Parkinson’s disease cognitive impairment (Poster Number: 522)
Presentation Title: The NMDAr modulator NYX-458 does not worsen motor symptoms or interfere with L-Dopa’s anti-parkinsonian effect in a non-human primate Parkinson’s disease model.
(Poster Number: 521)
NYX-458 is a novel, oral NMDA receptor modulator currently in Phase 1 clinical development for the treatment of cognitive impairment associated with Parkinson’s disease. In preclinical studies in rodents and non-human primates, NYX-458 has demonstrated rapid, robust, and enduring effects on cognitive impairment. A Phase 1 study evaluating the safety, tolerability, pharmacokinetics, and CNS exposure of NYX-458 is ongoing, and
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the company’s business plans and objectives, therapeutic effects of the company’s product candidates, expectations regarding the design, implementation, timing, and success of its current and planned clinical trials, expectations regarding its preclinical development activities, and expectations regarding its uses and sufficiency of capital. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of the company’s product candidate development activities and planned clinical studies; the company’s ability to execute on its strategy; regulatory developments in
Stern Investor Relations
Source: Aptinyx Inc.
Source: Aptinyx Inc.